Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD-3463 (ALK/IGF1R inhibitor) , an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 11,000 | |||
10 mg | 在庫あり | ¥ 16,500 | |||
25 mg | 在庫あり | ¥ 29,000 | |||
50 mg | 在庫あり | ¥ 47,500 | |||
100 mg | 在庫あり | ¥ 85,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,500 |
説明 | AZD-3463 (ALK/IGF1R inhibitor) , an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency. |
ターゲット&IC50 | ALK:0.75 nM(Ki) |
In vitro | In vivo, AZD-3463 is equally effective against both the mutated L1196M and the wild-type ALK. When acting on transplanted tumors in vivo, AZD-3463 dose-dependently inhibits pALK, leading to the stagnation (H3122) or reduction (DEL, H2228) of tumor volume. |
In vivo | In various in vitro models resistant to Crizotinib, AZD3463 exhibits antiproliferative efficacy against five out of six cell lines, with a potency four times greater than that of the parent H3122 cells. AZD3463 is effective across tumor cell lines with ALK fusion, including DEL (ALCL NPM-ALK), H2228 (NSCLC EML4-ALK), and H3122 (NSCLC EML4-ALK), by inhibiting ALK and reducing its autophosphorylation. |
キナーゼ試験 | HDAC enzymatic assays: Tubastatin A is dissolved and diluted in assay buffer (50 mM HEPES, pH 7.4, 100 mM KCl, 0.001% Tween-20, 0.05% BSA, and 20 μM tris(2-carboxyethyl)phosphine) to 6-fold of the final concentration. HDAC enzymes are diluted to 1.5-fold of the final concentration in assay buffer and pre-incubated with Tubastatin A for 10 minutes before the addition of the substrate. The amount of FTS (HDAC1, HDAC2, HDAC3, and HDAC6) or MAZ-1675 (HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9) used for each enzyme is equal to the Michaelis constant (Km), as determined by a titration curve. FTS or MAZ-1675 is diluted in assay buffer to 6-fold the final concentration with 0.3 μM sequencing grade trypsin. The substrate/trypsin mix is added to the enzyme/compound mix and the plate is shaken for 60 seconds and then placed into a SpectraMax M5 microtiter plate reader. The enzymatic reaction is monitored for release of 7-amino-4-methoxy-coumarin over 30 minutes, after deacetylation of the lysine side chain in the peptide substrate, and the linear rate of the reaction is calculated. |
別名 | ALK/IGF1R inhibitor |
分子量 | 448.95 |
分子式 | C24H25ClN6O |
CAS No. | 1356962-20-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 23 mg/mL (51.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AZD-3463 1356962-20-3 Angiogenesis Apoptosis Autophagy Tyrosine Kinase/Adaptors ALK IGF-1R Anaplastic lymphoma kinase (ALK) Anaplastic lymphoma kinase neuroblastoma kinase AZD3463 receptor PI3K/AKT/mTOR. pathway crizotinib CD246 resistance ALK tyrosine kinase receptor Inhibitor inhibit AZD 3463 ALK/IGF1R inhibitor Cluster of differentiation 246 tyrosine inhibitor